- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06025799
Nurse-Delivered Adapted MBSR During Breast Cancer Radiotherapy
Effects of a Nurse-Delivered, Adapted Mindfulness-Based Stress Reduction Intervention on Psychological Distress, Hope, and Mindfulness in Women With Breast Cancer Receiving Radiotherapy: A Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Egypt
-
Alexandria, Egypt, Egypt
- Alexandria Ayadi Al Mostakbal Oncology Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Adult women with non-metastatic breast cancer who were receiving post-mastectomy radiotherapy were eligible. Participants had to be within one to six months after mastectomy, able to read and write, able to communicate verbally, available for follow-up, and willing to provide informed consent and undergo randomization.
Ability to read and write was required because participants completed self-administered outcome questionnaires and used written intervention materials, home-practice instructions, and weekly practice diaries.
Exclusion Criteria:
Participants were excluded if they had metastatic disease, current alcohol or drug misuse, serious comorbid conditions such as renal, cardiac, or liver disease, or any condition that limited their ability to complete the study procedures or outcome assessments.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Adapted mindfulness-based stress reduction plus routine radiotherapy care
Adapted mindfulness-based stress reduction plus routine radiotherapy care Participants continued to receive the centre's standard radiotherapy-related services and also attended a four-week mindfulness programme facilitated jointly by two trained nurses.
The programme included eight structured group meetings and a practice-consolidation day.
Common facilitator guidance, participant materials, and audio resources were used throughout.
Between-session practice was supported through scheduled telephone contact and WhatsApp communication, and missed meetings were rescheduled.
|
Adapted mindfulness-based stress reduction The behavioural programme combined breathing focused attention, body-awareness exercises, seated meditation, gentle mindful movement, education about stress responses, group reflection, and guided practice outside the sessions.
Both facilitators followed the same delivery guide and used uniform materials.A researcher who did not deliver the intervention observed implementation using a structured fidelity checklist.
|
|
No Intervention: Routine-care Arm
Routine-care Arm Participants assigned to the comparison arm continued with the oncology centre's established radiotherapy pathway, including routine nursing care, medical review, symptom monitoring, and access to available supportive or referral services.
After completion of the final study assessment, the mindfulness programme was offered to those who wished to receive it.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in mindfulness assessed by the Five Facet Mindfulness Questionnaire (FFMQ)
Time Frame: Baseline, immediately after the 4-week intervention, and approximately 1 month after intervention completion.
|
The FFMQ is a 39-item self-report measure covering observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity.
Items are rated from 1 to 5. The total score ranges from 39 to 195, with higher scores reflecting greater mindfulness.
|
Baseline, immediately after the 4-week intervention, and approximately 1 month after intervention completion.
|
|
Change in psychological distress assessed by the Depression Anxiety and Stress Scale-21 (DASS-21) total score
Time Frame: Baseline, immediately after the 4-week intervention, and approximately 1 month after intervention completion.
|
The DASS-21 contains 21 self-report items divided into depression, anxiety, and stress subscales.
Items are rated from 0 to 3. The seven items within each subscale are summed and multiplied by two, producing depression, anxiety, and stress scores ranging from 0 to 42.
The overall psychological-distress score is calculated as the sum of the three scaled subscale scores and ranges from 0 to 126.
Higher scores indicate greater psychological distress.
|
Baseline, immediately after the 4-week intervention, and approximately 1 month after intervention completion.
|
|
Change in hope assessed by the Herth Hope Index (HHI)
Time Frame: Baseline, immediately after the 4-week intervention, and approximately 1 month after intervention completion.
|
The HHI is a 12-item self-report measure of hope.
Items are rated on a four-point scale from 1 to 4. Items 3 and 6 are reverse scored before calculation of the total score.
Total scores range from 12 to 48, with higher scores indicating greater hope.
The measure includes temporality and future, positive readiness and expectancy, and interconnectedness.
|
Baseline, immediately after the 4-week intervention, and approximately 1 month after intervention completion.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00013620/8/2023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.